SPY310.52+2.16 0.70%
DIA257.31-0.56 -0.22%
IXIC10,154.63+95.86 0.95%

Cantor Fitzgerald Maintains Overweight on Inovio Pharmaceuticals, Raises Price Target to $45

Cantor Fitzgerald analyst Charles Duncan maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $17 to $45.

Benzinga · -
Cantor Fitzgerald analyst Charles Duncan maintains Inovio Pharmaceuticals (NASDAQ: INO) with a Overweight and raises the price target from $17 to $45.